RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
Clinical trial NCT05821933 · RECRUITING
Trial details
- NCT number
- NCT05821933
- Sponsor
- RemeGen Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-07
- Primary completion
- 2025-09-01
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.